May 17th 2024
Amgen’s Tarlatamab-dlle (Imdelltra) is the first and only approved DLL3-targeting bispecific T-cell engager therapy for the aggressive form of lung cancer.
Continuing the Conversation in Myelofibrosis: The Role of Managed Care in Supporting Treatment Goals Through Appropriate Use of Emerging Therapies
1.0 Credits / Hematology, Oncology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
Navigating Long-Term Toxicities of CAR T-Cell Therapy: Educational Insights for Oncology Pharmacists
May 14, 2024 | 7:00 PM ET
View More
Mastering Immunotherapy-Based Approaches in Advanced Endometrial Cancer: A Pharmacist’s Perspective
May 15, 2024 | 7:00 PM ET
View More
Translating Insights Into Impact: Enhancing Treatment for HER2-Positive Metastatic Breast Cancer
May 16, 2024 | 7:00 PM ET
View More
Advances in EGFR Exon 20 Insertion-Positive Non–Small Cell Lung Cancer: A Focus on Specialty Pharmacy Interventions
1.5 Credits / Oncology, Pulmonology/Respiratory
View More
Clinical Updates in AML Induction and Maintenance Regimens and the Role of the Specialty Pharmacist
1.5 Credit(s) / Hematology, Oncology
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes and the Role of Oncology Pharmacists
1.5 Credit / Hematology, Oncology
View More
Improving Pharmacists' Knowledge of Endometrial Cancer and Solutions for Equity and Medication Access
1.5 Credits / Endocrinology, Diabetes & Metabolism, Oncology
View More
Enhancing Bruton Tyrosine Kinase Inhibitor Outcomes in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: A Pharmacist's Roadmap to Success
May 21, 2024 | 7:00 PM ET
View More
New Frontiers in the Treatment of Lower-Risk Myelodysplastic Syndromes: Bridging Clinical Innovation and Practice
May 22, 2024 | 7:00 PM ET
View More
Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
May 23, 2024 | 7:00 PM ET
View More
Live CE activities affiliated with the 2024 HOPA Annual Conference
May 14-23, 2024
View More
Managed Care Approaches to Improve Outcomes in Frontline Therapy for Advanced Renal Cell Carcinoma
1.0 Credit / Oncology
View More
Demystifying the Details of T-Cell Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
2.0 Credits / Oncology
View More
Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer
0.5 Credit / Oncology, Women’s Health
View More
Assessing the Role of Antibody-Drug Conjugates in Breast Cancer Treatment Pathways
1.0 Credit / Oncology
View More
Opportunities to Optimize Treatment of Non-Small Cell Lung Cancer and Gastric Cancers With Antibody-Drug Conjugates
1.0 Credit / Oncology
View More
The Impact of Antibody-Drug Conjugates in Bladder Cancer and Gynecologic Malignancies
1.0 Credit / Oncology
View More
Exploring the Value of Pharmacist-Led Toxicity Management for New and Emerging Antibody-Drug Conjugates Across Solid Tumors
1.25 Credits / Oncology
View More
Improving Patient Outcomes in TNBC: Immunotherapy, PARP, TROP2, Oh My!
2.0 Credits / Oncology
View More
A Pharmacologic Overview of Antibody-Drug Conjugates
2.0 Credits / Oncology
View More
Oncology Pharmacists Connect: Summer 2024
June 20-21, 2024
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Reducing Endocrinopathies of Immune Checkpoint Inhibitor Therapy: Management Strategies for Oncology Pharmacists
June 25, 2024 | 7:00 PM ET
View More
Supporting Safe, Effective, and Equitable Access to B-Cell Maturation Antigen (BCMA)-Directed Treatments in Multiple Myeloma: Strategies for Specialty and Managed Care Pharmac...
1.5 Credit / Hematology, Oncology
View More
Empowering Pharmacists to Improve Care for Patients with Myelofibrosis
1.0 Credit / Oncology
View More
Novel Therapeutic Approaches for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer: An Oncology Pharmacy Perspective
1.0 Credit / Oncology, Pulmonology/Respiratory
View More
Updates and Insights in Managing Anti-Androgen Therapies in Prostate Cancer
1.5 Credits / Oncology, Urology
View More
Exploring the Advancements in BTK Inhibitor Therapy for Mantle Cell Lymphoma and the Growing Impact of Oncology Pharmacists
1.0 Credit / Hematology, Oncology
View More
Navigating Ethical, Financial Considerations When Delivering Cancer Care
April 30th 2024“I think in those situations where you can use the lower cost of the drug, you should, because it's going to help the overall societal perspective. That begins to break down, though, when that low-cost drug is the one that you're losing money on,” said Scott Soefje in a Q&A on balancing cost and margin at a site of care.
FDA Requests Black Box Warning for Approved CAR-T Therapies Over Secondary Cancer Concern
January 24th 2024As per US law Section 505(o)(4), the manufacturers are required to make the requested changes, respond with a modified version of the requested changes for review, or respond with a rebuttal within 30 days of the FDA's ask.